Cost Evaluation of Basiliximab Treatment for Renal Transplant Patients in Japan

Author： Hasegawa T.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.21, Iss.11, 2003-01, pp. : 791-806

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Basiliximab: economic advantage for renal transplantation in Japan

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 405, 2003-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Immunosuppression in Older Renal Transplant Patients

By Morales J.M.  

Drugs & Aging, Vol. 16, Iss. 4, 2000-04 ,pp. : 279-287

Adis International

Access to resources Recommend Favorite

Adverse events: significant cost impact in renal transplant

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 562, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Early treatment with cinacalcet is more cost effective than delayed treatment for patients with hyperparathyroidism secondary to renal failure

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 529, 2007-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients

By Moes Dirk Jan A.R.   Press Rogier R.   >  

Clinical Pharmacokinetics, Vol. 51, Iss. 7, 2012-07 ,pp. : 467-480

Adis International

Access to resources Recommend Favorite